In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Apthera Inc.

Division of Sellas Life Sciences Group Inc.

Latest From Apthera Inc.

Galena’s NeuVax Mops Up Circulating Breast Cancer Cells To Prevent Metastases

Median five-year data from the Phase I/II NeuVax trial released at ASCO this June showed that among node-positive patients 25.9% of the control had a recurrence, while metastases surfaced in only 5.6% of NeuVax patients. Final gold standard five-year data for all patients were released at the San Antonio Breast Cancer Symposium Dec. 5; Galena launched a Phase III trial in January 2012.

BioPharmaceutical Clinical Trials

GSK taps new MD Anderson institute in $335m OX40 antibody deal

The University of Texas MD Anderson Cancer Center is continuing its legacy of licensing oncology discoveries to pharmaceutical companies via a collaboration with GlaxoSmithKline through which the cancer center may earn more than $335 million in upfront and milestone payments plus royalties on sales of therapeutic antibodies that activate OX40 receptors on the surface of T cells to mount an immune system attack.


Galena public offering raises $14.5M to support NeuVax studies

Galena Biopharma, a US oncology-focused company, said that it has closed on its underwritten public offering for gross proceeds of about $14.5 million. consisted of 9.75 million shares of its common stock at $1.50 per share,.


Galena nets $11.6mn from common stock offering to support NeuVax studies

Galena Biopharma, a US firm focused on oncology, will net $11.6 million to advance its cancer immunotherapy NeuVax from the sale of 8.5 million shares of common stock at $1.50 per share in an offering set to close on 11 April.

See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sellas Life Sciences Group Inc.
  • Senior Management
  • Mark W Schwartz, PhD, Pres. & CEO
    Robert E Kennedy, CFO
  • Contact Info
  • Apthera Inc.
    Phone: (480) 348-9707
    8418 E. Shea Blvd.
    Ste. 100
    Scottsdale, AZ 85260